This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

What Is a Compounding Pharmacy, and Why Did It Become a Weight-Loss Business?

A pharmacy built to mix one drug for one patient ended up supplying a third of a national craze, and the law is asking for its workshop back.

A pharmacist's workbench with a glass mortar and pestle, small amber vials and a balance scale beside rows of identical syringes.

A compounding pharmacy is a pharmacy where somebody still makes the medicine. Most pharmacies count pills that a manufacturer made in a factory, put them in an orange bottle and type a label. A compounder takes raw ingredients and mixes a drug for one particular patient, because the factory version does not fit that patient. Maybe it has a dye they are allergic to, or it only comes as a pill and they cannot swallow pills.

That is the traditional answer to what is a compounding pharmacy, and it is still the legal answer. The practical answer changed around 2022, when compounders started making copies of the new weight-loss drugs for a large share of the country. At peak in 2024, nearly 1 in 3 Americans taking a GLP-1 drug reported getting it from a compounding pharmacy. That is a lot of custom work. How a business built for the patient who cannot swallow pills ended up supplying a third of a national drug craze is a story about who gets paid for what, one link at a time.

What is a compounding pharmacy supposed to do?

Federal law, in Section 503A of the drug statute, allows patient-specific compounding “by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or by a licensed physician.” The key words are patient-specific. There is a prescription, it names a person, and the pharmacist makes that person’s drug.

Because it is one drug for one person, it gets a lighter rulebook. A 503A pharmacy compounding for a patient-specific prescription is exempt from the federal current good manufacturing practice rules that drug factories follow. These pharmacies are regulated mainly by state boards of pharmacy, not the FDA, and they do not have to register with the FDA. This makes sense. You do not want to inspect a pharmacist’s mortar and pestle like it is a plant producing a billion tablets (the mortar would not survive the audit).

The rulebook does have a line, though, and Wikipedia states it plainly. Making compounded medicines in advance batches, rather than for a specific person on demand, is called “non-traditional” or “officinal” compounding, and it “is akin to small-scale manufacturing.” Keep that word “manufacturing” in mind. The whole story is about how small “small-scale” stays.

Why the law lets a pharmacist copy a branded drug at all

Ordinarily it doesn’t. Compounding a copy of an FDA-approved drug is ordinarily prohibited, which also makes sense: if a factory makes a drug the FDA approved, a pharmacist mixing the same drug in the back room is not serving a special patient. It is just competing with the factory, with fewer inspections.

The exception is a shortage. If the approved drug is on the FDA’s drug shortage list, compounders may make it, on the theory that a patient who needs a drug the factory cannot supply has a pretty special need. Semaglutide and tirzepatide went on that list in 2022, when demand outran supply, and compounding pharmacies entered the market. One account of the period puts it bluntly: the shortage-list exception, “not any general right to compound popular medications,” is what allowed large-scale compounding of these drugs for several years.

So the legal machinery was simple. Factory can’t keep up, pharmacist fills the gap, gap closes, pharmacist goes back to the patient who can’t swallow pills. It’s fine. It is the sort of rule that works well when the gap is small.

How a shortage turned the exception into a supply chain

The gap was not small. The FDA approved Wegovy for weight loss in 2021, which helped drive a demand surge. Non-diabetic patients using GLP-1 drugs for weight loss went from 21,000 in 2019 to 174,000 in 2023, an increase of more than 700%. By August 2025, a survey found nearly 12% of Americans had used a GLP-1 for weight loss at some point.

Now follow the chain. A patient wants the drug and cannot find the branded version, or cannot afford it. A telehealth company sees the patient and gets paid for the visit (and, often, for a monthly subscription). A prescriber on the platform writes a prescription. A compounding pharmacy gets paid for each vial. Each link is doing something individually legal, and each link earns more the more patients go through.

It is easy to picture the conversation at some startup, which I am inventing: “Hey guys, the pharmacy is technically making a custom drug for each patient. What if each patient was the same patient, but more of them?” Nobody needs to say this out loud. The incentive says it.

The relationships got a little blurry. A visit, a prescription, a vial, a dosing chart, a sleek box, an automatic refill, a referral bonus. At some point the patient is not sure whether they have a doctor, a pharmacy or a subscription box, and the honest answer may be all three. To be fair, the FDA noticed: its warning letters to telehealth companies name the platform itself, not just the pharmacy, as responsible for misbranding the drug.

When a pharmacy starts working like a factory

Here is where the second meaning of “small-scale manufacturing” kicks in. A pharmacy built around one patient at a time was now producing for a third of a market, under rules written for one patient at a time. Those rules were not designed to answer factory questions, and the results were weird in the specific way factory problems are weird.

For instance, a pharmacovigilance study of the FDA’s adverse event reporting system compared compounded GLP-1 products to non-compounded ones. The reporting odds ratio for preparation errors was 48.92. Not 48, not 50. 48.92. I find it hard to look away from that number. It says that, among the reports in that database, preparation errors showed up in compounded products at roughly forty-nine times the rate you would expect from the comparison drugs, measured to two decimal places, which is the kind of precision usually reserved for things that are going well. Contamination came in at 19.00 and compounding or manufacturing issues at 8.51. (A reporting ratio measures what people report, not a precise count of what happened, which the people who run these studies will tell you at length.)

Then there is the packaging. A factory pen clicks to a dose. A compounded vial comes with syringes and math. A 2023 case series of poison control calls described one patient who got a vial and syringes for self-administration “with no pharmacist counseling provided on proper drug administration.” America’s Poison Centers report a nearly 1,500% increase since 2019 in calls about overdoses or side effects of injectable weight-loss drugs. A vial plus syringes is, in everyday-life terms, a bit like being handed the flour and a recipe in a unit you have never used. (Here is where I admit my qualifications: I read warning letters for a living and have never mixed anything more sterile than a vinaigrette.)

I mean, the money got large too. The U.S. compounding pharmacy market was valued at roughly $6.98 billion in 2025 and is projected to reach $12.79 billion by 2035. The projection assumes 6.24% annual growth, which, for an industry that just went through what this one went through, is a strikingly calm number.

What happens when the shortage ends

The exception was tied to the shortage, so when the drugs came off the shortage list, the exception was supposed to go with them. (The site covers the delistings in detail elsewhere.) On the other hand, a business that has customers, payroll and a refill schedule does not simply stop. It looks for a new reason.

One reason is that a compounder may still make a drug for a patient who needs a significant difference from the branded product. That is the original purpose of compounding, still sitting in the law. Which brings us to a warning letter the FDA sent on September 18, 2026, to a Houston compounding pharmacy, citing “pretextual” significant-difference determinations, boilerplate prescribing records, and sterile compounding failures including inadequate smoke studies and rewritten media fill records. The same day, BioSpace reported, the FDA sent a warning letter to Empower Clinic Services, doing business as Empower Pharmacy, over risk of contaminating drugs “with filth.”

There are two ways to read this. One is that the chain bent the law: a rule written for the allergic patient got stretched to cover a mass market, and boilerplate is what stretching looks like on paper. The other is that the law did exactly what it said. A shortage happened, the statute said pharmacies could fill it, they filled it, and the trouble is that “fill the gap” never specified a maximum gap. Both readings fit the same facts. The documents do not settle which one is right.

Anyway, the FDA is also closing the bigger door. According to ArentFox Schiff, a May 2026 proposal, if finalized, would “close the last remaining regulatory pathway for large-scale compounding” of semaglutide, tirzepatide and liraglutide by 503B outsourcing facilities (the larger, FDA-registered kind of compounder, covered in their own article here). Whether it is finalized is not settled.

Where the chain ended up

Look, nobody set out to turn the neighborhood compounding pharmacy into a weight-loss manufacturer. The patient wanted a drug. The platform wanted the visit fee. The prescriber wanted to help. The pharmacy wanted to sell vials. The law wanted to cover a shortage. Each wish was reasonable, and added together they produced a factory regulated as a workshop.

The workshop is now being asked to be a workshop again, for patients who are each, individually and on paper, different. If you run a compounding pharmacy and want to stay in the weight-loss business, you had better make sure every patient’s significant difference is both significant and different.

Sources

  1. Compounded GLP-1s: Why doctors worry and the FDA is cracking down
  2. cGMP Expectations for Outsourcing Facilities
  3. 21 U.S. Code § 353a - Pharmacy compounding | U.S. Code | US Law | LII / Legal Information Institute
  4. The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
  5. Compounded GLP-1 Marketing After the Shortage Ended
  6. How GLP-1s Broke Healthcare Distribution | Contrary Research
  7. Compounding - Wikipedia
  8. Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
  9. Quality Control In Compounding Pharmacy: 2026 Checklist
  10. Semaglutide Salt Forms: Why the Base Matters
  11. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
  12. Compounding After a Drug Leaves the Shortage List
  13. FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’ - BioSpace
  14. America's Poison Centers - GLP-1
  15. Administration errors of compounded semaglutide reported to a poison control center-Case series
  16. FDA Warning Letters to Telehealth Companies Selling Compounded Drugs

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next